|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A mini review on cancer of un- known primary site: A clinical puzzle for the oneologists 显示文摘 | Pavlidis N Khaled H Gaafar R | 2015 | J Adv Res2015，6，3： | 1 |
| 2 | A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pamatrexed and cisplatin for advanced, non- squamous, non-small cell lung cancer 显示文摘 | Mubarak N Gaafar R Shehata S | 2012 | BMC Cancer2012，12，9： | 1 |
| 3 | Short - term treatment - related symptoms and quality of life: results from an international randomized phase III study of cispla- tin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung - Cancer Group and National Cancer Institute, Canada, Intergroup Study 显示文摘 | Bottomley A Gaafar R Manegold C | 2006 | J Clin Oneol2006，24，9： | 1 |
| 4 | Phase II , openlabel, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage III b or IV ) non-small-cell lung cancer显示文摘 | Curer T Vrdoljak E Gaafar R | 2006 | Anticaner Drugs2006，17，4： | 1 |
| 5 | Randomized phase Ⅲ study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada 显示文摘 | van Meerbeeck JP Gaafar R Manegold C | 2005 | J Clin Oncol2005，23，28： | 1 |
| 6 | Phase Ⅱ, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲ b or Ⅳ) non small cell lung cancer显示文摘 | Curer T Vrdoljak E Gaafar R et aI | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 7 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib(IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ) non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticaneer Drugs2006，17，4： | 1 |
| 8 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲ b or Ⅳ) non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 9 | Short-term treat- ment-related symptoms and quality of life: results from an international randomized phase Ill study of cisplatin with or without raltitrexed in patients with malignant pleural meso- thelioma 显示文摘 | Bottomley A Gaafar R Manegold C | 2006 | J Clin Oncol2006，54，9： | 1 |
| 10 | Randomized phaseID study of cisplatin with or without raltitrexed in patients with ma-lignant pleural mesothelioma: an intergroup study of the EuropeanOrganisation for Research and Treatment of Cancer Lung CancerGroup and the National Cancer Institute of Canada显示文摘 | Van Meerbeeck JP Gaafar R Manegold C | 2005 | J Clin Oncol2005，23，28： | 1 |
| 11 | Randomi- zed phase HI study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma :an inter- group study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the Na- tional Cancer Institute of Canada显示文摘 | Van Meerbeeck JP Gaafar R Manegold C | 2005 | J Clin Oncol2005，23，28： | 1 |
| 12 | Randomized phase Ⅲ study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma:an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Institute of Canada显示文摘 | van Meerbeeck JP Gaafar R Manegold C | 2005 | J Clin Oncol2005，23，： | 1 |
| 13 | Short-term treatment -related symptoms and quality of life:resultsfrom an international randomized phase Ⅲ study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma:an EORTC LungCancer Group and National Cancer Institute,Canada,Intergroup Study显示文摘 | Bottomley A Gaafar R Manegold C | 2006 | J Clin Oncol2006，24，9： | 1 |
| 14 | Phase Ⅱ, open_label, randomized study(SIGN) of singleagent gefitinib(IRESSA) or docetaxel as second_line therapy in patients with advanced(stage Ⅲb or Ⅳ) non_small_cell lung cancer显示文摘 | Curer T Vrdoljak E Gaafar R | 2006 | Anticancer Dnlgs2006，17，4： | 1 |
| 15 | A double- blind, randomised, placebo-controlled phase III inter- group study of gefitinib in patients with advanced NS- CLC,non-progressing after first line platinum-based chemotherapy(EORTC 08021/ILCP 01/03)显示文摘 | Gaafar R M Surmont V F Scagliotti G V | 2011 | Eur J Cancer2011，47，15： | 1 |
| 16 | Short-term treatment-related symptoms and quality of life:Results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma:an EORTC Lung-Cancer Group and National Cancer Inst显示文摘 | Bottomley A Gaafar R Manegold C | | 0，，： | 1 |
| 17 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ)non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 18 | A randomized,phase 2study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced,non-squamous,nonsmall cell lung cancer显示文摘 | Mubarak N Gaafar R Shehata S | 2012 | BMC Cancer2012，12，1： | 1 |
| 19 | PhaseⅡ,open-label,randomized study(SIGN)of single-agent gefitinib(IRESSA)or docetaxel as second-line therapy in patients with advanced(stageⅢb orⅣ)non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anti-Cancer Drug2006，17，4： | 1 |
| 20 | Application of well log analysis for source rock evaluation in the Duwi Formation, Southern Gulf of Suez, Egypt显示文摘 | El Sharawy M S Gaafar G R | 2012 | Journal of Applied Geophysics2012，80，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员